Parkwood LLC Chemo Centryx, Inc. Transaction History

Parkwood LLC

$1.42 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $694,058 - $1.04 Million	-52,660 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $355,808 - $1.89 Million	37,102 Added 238.48%	52,660 $705,000
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $93,364 - $128,934	-1,885 Reduced 10.81%	15,558 $797,000
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $558,353 - $769,995	-11,817 Reduced 40.39%	17,443 $1.08 Million
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $260,162 - $346,265	5,613 Added 23.74%	29,260 $2.09 Million
Q2 2020 Aug 11, 2020	BUY	$38.58 - $65.07 $912,301 - $1.54 Million	23,647 New	23,647 $1.36 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.